A novel Immunotherapy Combination in relapsed/refractory Multiple Myeloma: Updated Analysis of Phase 1b Data for Talquetamab, a GPRC5DxCD3 bispecific Antibody, in Combination with Daratumumab

被引：0

作者：

Kortuem, K. M. ^{[1
]}

Bahlis, N. ^{[2
]}

Mateos, M. -V. ^{[3
]}

Weisel, K. ^{[4
]}

Dholaria, B. ^{[5
]}

Garfall, A. ^{[6
]}

Goldschmidt, H. ^{[7
,8
]}

Martin, T. ^{[9
]}

Morillo, D. ^{[10
]}

Reece, D. ^{[11
]}

Hurd, D. ^{[12
]}

Rodriguez-Otero, P. ^{[13
]}

Bhutani, M. ^{[14
]}

D'Souza, A. ^{[15
]}

Oriol, A. ^{[16
,17
,18
]}

Askari, E. ^{[19
]}

San-Miguel, J. ^{[20
]}

van de Donk, N. ^{[21
]}

Vishwamitra, D. ^{[22
]}

Lin, Wang S. X. ^{[22
]}

Prior, T. ^{[22
]}

Vandenberk, L. ^{[23
]}

Smit, Damiette M. -A. ^{[24
]}

Goldberg, J. ^{[25
]}

Waesch, R. ^{[26
]}

Chari, A. ^{[27
]}

机构：

[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany

[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[3] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[4] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Univ Hosp Heidelberg, Internal Med, Heidelberg, Germany

[8] Natl Ctr Tumor Dis, Heidelberg, Germany

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

[10] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Wake Forest Univ, Ctr Comprehens Canc, Dept Internal Med, Sect Hematol & Oncol, Winston Salem, NC 27101 USA

[13] Clin Univ Navarra, Navarra, Spain

[14] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[15] Med Coll Wisconsin, Milwaukee, WI USA

[16] Inst Catala Oncol, Badalona, Spain

[17] Inst Josep Carreras, Badalona, Spain

[18] Hosp Badalona Germans Trias & Pujol, Badalona, Spain

[19] Fdn Jimenez Diaz Univ Hosp, Dept Hematol, Madrid, Spain

[20] Clin Univ Navarra, CCUN, CIMA, CIBERONC,IDISNA, Pamplona, Spain

[21] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands

[22] Janssen Res & Dev, Spring House, PA USA

[23] Janssen Res & Dev, Beerse, Belgium

[24] Janssen Res & Dev, Los Angeles, CA USA

[25] Janssen Res & Dev, Raritan, NJ USA

[26] Univ Freiburg, Freiburg, Germany

[27] Mt Sinai Sch Med, New York, NY USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P431

引用

页码：144 / 145

页数：2

共 50 条

[1] Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
Purcell, Kiah
Catamero, Donna
Dai, Victoria
Feuer, Julia
Giacoia, Leora
Leon, Yan
Lurie, Alaina
Mitchell, Emily
Ray, Chloe
Urena, Annel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S313
[2] MANAGEMENT CONSIDERATIONS FOR DERMATOLOGIC TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA
Esler, Elaine
Ray, Chloe
Hefner, Kayla
O'Rourke, Lisa
Gray, Kathleen
McCluggage, Julie
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[3] MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Shenoy, Samantha
Leahey, Sheryl
Catamero, Donna
O'Rourke, Lisa
Gray, Kathleen
Rogers, Stephanie
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[4] Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Verkleij, Christie P. M.
Broekmans, Marloes E. C.
van Duin, Mark
Frerichs, Kristine A.
Kuiper, Rowan
de Jonge, A. Vera
Kaiser, Martin
Morgan, Gareth
Axel, Amy
Boominathan, Rengasamy
Sendecki, Jocelyn
Wong, Amy
Verona, Raluca, I
Sonneveld, Pieter
Zweegman, Sonja
Adams, Homer C., III
Mutis, Tuna
van de Donk, Niels W. C. J.
BLOOD ADVANCES, 2021, 5 (08) : 2196 - 2215
[5] Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1
Catamero, Donna
Purcell, Kiah
Ray, Chloe
Giacoia, Leora
Leahey, Sheryl
Born, Patricia
Kruyswijk, Sandy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S314 - S315
[6] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
Schinke, Carolina D.
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Rasche, Leo
Ye, Jing Christine
Vishwamitra, Deeksha
Ma, Xuewen
Qin, Xiang
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi
Tolbert, Jaszianne A.
Renaud, Thomas
Goldberg, Jenna
Heuck, Christoph
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study
Searle, Emma
Quach, Hang
Biran, Noa
Perrot, Aurore
Berdeja, Jesus G.
Dorritie, Kathleen
Van Elssen, Catharina
Touzeau, Cyrille
Anguille, Sebastien
Vishwamitra, Deeksha
Nguyen, Ashley
Ghosh, Debopriya
Shearin, Elizabeth
Mason, Gary E.
Renaud, Thomas
Matous, Jeffrey
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S550
[8] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
Schinke, C.
Touzeau, C.
Minnema, M. C.
van de Donk, N. W.
Rodriguez-Otero, P.
Mateos, M. -V.
Rasche, L.
Ye, J. C.
Vishwamitra, D.
Ma, X.
Qin, X.
Campagna, M.
Masterson, T.
Hilder, B.
Tolbert, J.
Renaud, T.
Goldberg, J.
Heuck, C.
Chari, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
[9] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
Ito, Shigeki
Kuroda, Yoshiaki
Sunami, Kazutaka
Matsue, Kosei
Imada, Kazunori
Tamura, Hideto
Takamoto, Mikihiro
Yamazaki, Hiroshi
Fujikawa, Ei
Pei, Lixia
Masterson, Tara J.
Campagna, Michela
Lau, Bonnie W.
Takamatsu, Yasushi
BLOOD, 2024, 144 : 7011 - 7012
[10] Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study
Shkury, Eden
Hellou, Tamer
Nevo, Lee
Avigdor, Abraham
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S88 - S89

← 1 2 3 4 5 →